United States Patent 11,806,334: Claim Scope, Expiration Risk, Orange Book Position, and Dexmedetomidine Patent Landscape

U.S. Patent No. 11,806,334 protects a narrow dosing regimen for dexmedetomidine oromucosal treatment of severe agitation in patients with schizophrenia or bipolar I or II disorder who have severe hepatic impairment. The independent claim requires three administration events, fixed doses of 90 mcg, 60 mcg, and 60 mcg, minimum two-hour spacing, a 210 mcg daily ceiling, and an oromucosal formulation. Dependent claims add a PEC score threshold, Child-Pugh Class C impairment, and specified water-soluble polymers, including hydroxypropyl cellulose.

The patent is a method-of-use and dosing patent. It does not, based on the quoted claims, broadly claim dexmedetomidine, all oromucosal formulations, or every treatment of agitation. Its commercial relevance depends on whether a competing product label, clinical protocol, or actual use practices adopt the claimed severe-hepatic-impairment regimen.

What does U.S. Patent 11,806,334 claim?

The patent’s claim set has five layers:

Claim	Protected subject matter	Key limitation
1	Treatment method	Three doses of dexmedetomidine in an oromucosal formulation for severe agitation with severe hepatic impairment
2	Clinical definitions	PEC score of at least 20 and Child-Pugh Class C
3	Formulation limitation	At least one water-soluble polymer
4	Polymer alternatives	HPC, HPMC, HEC, carboxymethylcellulose, methylcellulose, PEO, or mixtures
5	Narrowest formulation limitation	Hydroxypropyl cellulose

Claim 1 requires administration of:

An initial 90 mcg dose.
A second 60 mcg dose at least two hours after the initial dose and within 24 hours of it.
A third 60 mcg dose at least two hours after the second dose and within 24 hours of the initial dose.
A maximum total daily dosage of 210 mcg.
Dexmedetomidine or a pharmaceutically acceptable salt.
An oromucosal formulation.
Treatment of agitation associated with schizophrenia or bipolar I or II disorder.
A human subject with severe hepatic impairment.
Severe agitation.

The three claimed doses total exactly 210 mcg. The daily maximum therefore operates as both a dosage ceiling and a limitation matching the claimed regimen.

[U.S. Patent No. 11,806,334, claims 1-5.]

How narrow is the independent claim?

Claim 1 is narrow because infringement requires the combination of every material limitation. A competing regimen that changes any of the following may fall outside the literal scope of claim 1:

Initial dose below or above 90 mcg.
Second or third dose different from 60 mcg.
More than two hours between doses.
Third dose administered more than 24 hours after the initial dose.
Total daily dose above 210 mcg.
A non-oromucosal route.
A patient without severe hepatic impairment.
Agitation unrelated to schizophrenia or bipolar I or II disorder.

The claim does not require a particular trade name, dosage form geometry, film thickness, backing layer, flavor system, excipient ratio, or manufacturing process. “Oromucosal formulation” is the central dosage-form limitation. The claim is therefore broader than a claim limited to a particular sublingual film composition, but narrower than a claim covering all dexmedetomidine films or all dexmedetomidine treatment methods.

The claim also does not expressly require the product to be administered in a hospital, emergency department, psychiatric unit, or other specific setting. An administration in any setting could satisfy the claim if the remaining limitations are met.

What does claim 2 add to the patent scope?

Claim 2 converts two clinical concepts into objective thresholds:

Severe agitation is defined as a Positive and Negative Syndrome Scale - Excited Component, or PEC, score of at least 20.
Severe hepatic impairment is defined as Child-Pugh Class C.

This limitation reduces factual disputes over the meaning of “severe,” but it also creates proof requirements. A patent owner would need evidence that the treated patient met the stated clinical classification. A medical record showing a lower PEC score, no recorded PEC assessment, or hepatic impairment classified as Child-Pugh A or B could weaken a direct infringement case under claim 2.

Claim 1 itself uses “severe” without the numerical definitions supplied by claim 2. A product or treatment protocol could potentially fall within claim 1 while avoiding claim 2 if the patient’s condition is severe but not documented using the specified PEC and Child-Pugh classifications.

What formulation patents are implicated by claims 3 through 5?

Claims 3 through 5 add polymer limitations to the method of claim 1.

Claim 3 requires at least one water-soluble polymer. Claim 4 identifies seven alternatives:

Hydroxypropyl cellulose.
Hydroxypropyl methylcellulose.
Hydroxyethyl cellulose.
Carboxymethylcellulose.
Methylcellulose.
Polyethylene oxide.
Mixtures of those materials.

Claim 5 narrows the formulation to hydroxypropyl cellulose, commonly abbreviated HPC.

These claims are not composition claims in the quoted form. They require administration of a formulation containing the polymer in the claimed treatment regimen. A product containing HPC could implicate claim 5 only if it is also used with the claimed indication, patient population, dosing schedule, route, and daily maximum.

A competing manufacturer could attempt to design around claims 3 through 5 by using a non-listed water-soluble polymer or a formulation that does not contain a water-soluble polymer. That design-around would not avoid claim 1 if the formulation still qualifies as an oromucosal formulation and the other claim 1 limitations are met.

What is the relationship between the patent and IGALMI?

IGALMI is dexmedetomidine hydrochloride sublingual film approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar disorder I or II in adults. The FDA-approved product is administered sublingually, placing it within the general oromucosal dosage-form category used in the patent claims.[1]

The FDA label identifies dosing, hepatic impairment, warnings, and administration instructions. The label is commercially important because an approved label can provide evidence of induced infringement when it instructs users to perform a patented method. A patent analysis must compare the exact label instructions with the patent’s required 90/60/60 mcg regimen and 210 mcg maximum.

The patent should not be treated as covering all IGALMI use automatically. Patent coverage depends on the overlap between:

The approved product’s formulation.
The labeled dose.
The labeled timing of repeat doses.
The labeled hepatic-impairment instructions.
The labeled disease indications.
The patient’s documented severity.

[U.S. Food and Drug Administration, 2022.]

What is the FDA regulatory status of dexmedetomidine oromucosal therapy?

The FDA approved IGALMI in April 2022 for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.[1] This approval established a U.S. small-molecule product category distinct from injectable dexmedetomidine products used for sedation.

The regulatory status matters for patent enforcement because an ANDA applicant seeking approval of a generic version of the product must address listed patents under the Hatch-Waxman framework. An applicant may certify that a listed patent is invalid, unenforceable, or will not be infringed, or may seek approval after patent expiration under the applicable statutory pathway.[2]

The patent claims here are method claims. A generic applicant may pursue a label strategy that removes or omits a patented use, where permitted by FDA labeling rules. That strategy is more difficult when the patented dosing regimen is embedded in the approved use or when the product’s prescribing information instructs the claimed conduct.

What is the Orange Book status of U.S. Patent 11,806,334?

The Orange Book question cannot be answered from the claim text alone. Orange Book listing is a regulatory record separate from patent issuance. A patent may be relevant to an approved product without every claim being listed, and listing practices depend on the patent’s relationship to the approved drug, formulation, or method of use.[3]

For this patent, the relevant Orange Book analysis has three parts:

Issue	Relevance
Product association	Whether the patent is listed against IGALMI or a corresponding approved dexmedetomidine product
Claim category	Whether FDA accepts the claims as covering an approved method of use
Listing date and expiration	Whether the patent creates a current ANDA certification or approval-barrier issue

The patent’s method-of-use character makes its listing position more consequential than its existence alone. If listed, an ANDA applicant could face a Paragraph IV certification and potential litigation under 21 U.S.C. § 355(j). If not listed, the patent could still support infringement litigation based on commercial conduct, but it would not necessarily create the same ANDA approval mechanics.

When does U.S. Patent 11,806,334 lose exclusivity?

The patent was granted on December 5, 2023.[4] The statutory expiration date cannot be established from the issued claims or grant date alone. U.S. patent term generally runs 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and priority-chain analysis.[5]

The relevant exclusivity dates are therefore distinct:

Exclusivity category	Applicable analysis
Patent term	Based on the effective filing and priority chain, with PTA or terminal disclaimer adjustments
FDA new-drug exclusivity	Separate from the patent and based on the approval and statutory exclusivity category
Orphan-drug exclusivity	Applies only if the product received an orphan designation and approval for the protected indication
Pediatric exclusivity	May add six months if FDA requirements were satisfied
Regulatory data exclusivity	Applies independently of patent expiration

Patent 11,806,334 does not receive a new 20-year term merely because it issued in 2023. Its expiration depends on the earliest relevant nonprovisional application in its priority chain. Any terminal disclaimer could also cause it to expire with an earlier related patent.

Which companies are most exposed to this patent?

The primary commercial exposure is BioXcel Therapeutics and any partner, licensee, or successor commercializing dexmedetomidine oromucosal therapy for acute agitation. A generic applicant seeking to market an equivalent sublingual dexmedetomidine product would be the most likely Paragraph IV challenger if the patent is listed and relevant to the proposed label.

Potentially exposed parties include:

Generic manufacturers filing an ANDA for dexmedetomidine sublingual film.
Contract manufacturers producing the patented formulation for an infringing use.
Telepsychiatry, emergency-care, or institutional protocols that direct the claimed dosing regimen.
Developers of alternative oromucosal dexmedetomidine products.
Licensees using HPC-containing films for the claimed patient population.

There is no basis in the quoted claims alone to identify a particular licensing agreement or settlement. Patent ownership, licensing, and litigation rights must be distinguished. Assignment to a company does not establish that the company has licensed the patent to another commercial entity.

Are there biosimilar risks for dexmedetomidine?

No conventional biosimilar pathway applies. Dexmedetomidine is a chemically synthesized small molecule, not a biologic subject to the Public Health Service Act biosimilar framework.

The relevant competitive threat is an FDA-approved generic or other small-molecule competitor, usually through an ANDA or, depending on the product and formulation, a 505(b)(2) application. The principal barriers are formulation equivalence, pharmacokinetic performance, manufacturing controls, labeling, and patent certifications rather than biosimilarity.

What Paragraph IV challenges could target this patent?

A Paragraph IV challenge could attack the patent on several grounds:

Anticipation

A challenger could argue that an earlier reference disclosed all elements of claim 1, including:

Dexmedetomidine in an oromucosal dosage form.
Treatment of agitation associated with schizophrenia or bipolar disorder.
Severe hepatic impairment.
The 90/60/60 mcg sequence.
The two-hour minimum interval.
The 210 mcg maximum.

Because claim 1 is highly specific, a single-reference anticipation case would require a close match to the full regimen. General disclosure of dexmedetomidine, sublingual delivery, or hepatic dose reduction would not by itself anticipate the complete claim.

Obviousness

Obviousness is the more significant validity risk. A challenger could combine prior art concerning:

Dexmedetomidine pharmacology.
Sublingual or buccal delivery.
Dose reduction in hepatic impairment.
Repeat dosing for acute agitation.
Clinical severity classifications.
Water-soluble polymer film systems.

The patent owner would likely rely on the specific regimen, clinical tolerability, reduced exposure in severe hepatic impairment, and the relationship between hepatic clearance and dose selection. Evidence of unexpected safety or efficacy could strengthen the patent position.

Written description and enablement

The claims require treatment of severe agitation in Child-Pugh Class C patients using a precise multi-dose regimen. A challenge could examine whether the specification adequately supports the full scope of the claimed patient population and dosing schedule, especially if the clinical dataset for severe hepatic impairment was limited.

Indefiniteness

Terms such as “oromucosal formulation,” “severe agitation,” and “maximum total daily dosage” could generate claim-construction disputes. Claim 2 reduces ambiguity for PEC and Child-Pugh classifications, but claim 1 remains broader on the definitions of severe agitation and severe hepatic impairment.

What patent litigation affects U.S. Patent 11,806,334?

The supplied claim text does not establish a filed infringement action, ANDA litigation case, or settlement involving Patent 11,806,334. A patent grant alone does not show that a generic company has filed a Paragraph IV certification or that litigation has commenced.

The main litigation triggers would be:

FDA acceptance of an ANDA referencing the relevant dexmedetomidine product.
A Paragraph IV notice to the patent owner.
Filing of an action within the statutory period under 21 U.S.C. § 355(j).
A commercial launch before patent expiration.
Alleged induced infringement based on a generic label or promotional materials.

Settlement agreements can include delayed entry, licensed launch dates, supply arrangements, or restrictions on the approved label. No settlement term can be inferred from the patent claims.

How strong is the patent estate for dexmedetomidine oromucosal treatment?

Patent 11,806,334 is strong against exact use of the claimed severe-hepatic-impairment regimen but weaker as a broad barrier to the technology.

Estate characteristic	Assessment
Disease indication	Moderate protection; limited to schizophrenia or bipolar I or II agitation
Route	Moderate protection; limited to oromucosal delivery
Dose	Strong literal specificity; 90/60/60 mcg sequence and 210 mcg ceiling
Patient population	Strong limitation; severe hepatic impairment and severe agitation
Formulation	Broad in claim 1, narrower in claims 3-5
Generic design-around potential	Material; altered dose, route, timing, polymer, or patient population may avoid literal infringement
Biosimilar exposure	Not applicable
ANDA relevance	Depends on Orange Book listing and the proposed generic label

The patent’s commercial value is concentrated rather than broad. It can protect a clinically important high-risk subgroup, but it does not prevent every generic or alternative product from treating agitation with dexmedetomidine.

What generic launch scenarios exist?

Scenario 1: Exact-label generic launch

A generic applicant copies the product’s oromucosal dosage form and dosing instructions, including the severe hepatic impairment regimen. This presents the highest infringement and Paragraph IV risk.

Scenario 2: Carved-out labeling

The applicant omits the patented severe-hepatic-impairment regimen if FDA permits a legally effective use carve-out. The commercial value of the generic depends on whether the remaining label supports substantial noninfringing use.

Scenario 3: Different dose or schedule

A generic uses a different initial dose, repeat dose, interval, or maximum daily dose. This may avoid literal infringement of claim 1, although the patent owner could evaluate infringement under the doctrine of equivalents.

Scenario 4: Alternative formulation

A competitor develops a different oromucosal formulation without the claimed polymer, particularly without HPC. This may avoid claims 3-5 but will not necessarily avoid claim 1.

Scenario 5: Different route

An injectable, transdermal, oral, or intranasal dexmedetomidine product would generally avoid the oromucosal limitation, subject to separate patents and regulatory requirements.

Key Takeaways

U.S. Patent 11,806,334 is a narrow method-of-treatment patent for dexmedetomidine oromucosal dosing.
Claim 1 requires a 90 mcg initial dose, two 60 mcg repeat doses, at least two-hour spacing, administration within 24 hours, and a 210 mcg daily maximum.
The claimed patient must have severe hepatic impairment and severe agitation associated with schizophrenia or bipolar I or II disorder.
Claim 2 narrows the population to PEC scores of at least 20 and Child-Pugh Class C hepatic impairment.
Claims 3-5 add water-soluble polymer limitations, with claim 5 specifically requiring hydroxypropyl cellulose.
The patent does not broadly cover all dexmedetomidine, all sublingual films, or all treatment of agitation.
Generic risk is more relevant than biosimilar risk because dexmedetomidine is a small molecule.
The patent’s Orange Book impact depends on whether it is listed against the relevant approved product and whether a generic label overlaps the claimed method.
Exact-label generic entry creates the highest infringement risk; dose, timing, route, and formulation changes provide potential design-around paths.
Patent expiration must be calculated from the priority and nonprovisional filing chain, not from the December 5, 2023 grant date.

FAQs

Does Patent 11,806,334 cover all IGALMI dosing?

No. It covers only the claimed combination of indication, severe hepatic impairment, severe agitation, oromucosal administration, dose sequence, timing, and daily maximum.

Can a generic avoid the patent by using a 120 mcg initial dose?

Potentially. A 120 mcg initial dose would not literally satisfy claim 1’s required 90 mcg initial dose, although other patents, regulatory requirements, or doctrine-of-equivalents arguments could remain relevant.

Does an HPC-free sublingual film avoid the entire patent?

No. It could avoid claim 5 and possibly claims 3-4, but claim 1 does not require a water-soluble polymer. The product would still need to avoid the independent claim’s dosing and patient-population limitations.

Is Child-Pugh Class C required for infringement of claim 1?

No. Child-Pugh Class C is expressly required by claim 2. Claim 1 requires severe hepatic impairment but does not itself provide the Child-Pugh Class C definition.

Could an alternative dexmedetomidine formulation receive FDA approval before this patent expires?

Yes. FDA approval and patent freedom to operate are separate questions. A product could receive approval while remaining exposed to listed patents, unlisted patents, or infringement claims depending on its formulation, label, and commercial conduct.

References

U.S. Food and Drug Administration. (2022). IGALMI (dexmedetomidine hydrochloride) sublingual film: Prescribing information. FDA.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
U.S. Food and Drug Administration. (2024). Patent listing requirements and the Orange Book. FDA.
United States Patent and Trademark Office. (2023). U.S. Patent No. 11,806,334, Methods of treating agitation. USPTO.
United States Code. (2024). 35 U.S.C. §§ 154, 156, and 271; 21 U.S.C. § 355(j). Government Publishing Office.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bioxcel	IGALMI	dexmedetomidine hydrochloride	FILM;BUCCAL, SUBLINGUAL	215390-001	Apr 5, 2022		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER BY SUBLINGUAL OR BUCCAL ADMINISTRATION IN PATIENTS WITH SEVERE HEPATIC IMPAIRMENT	⤷ Start Trial
Bioxcel	IGALMI	dexmedetomidine hydrochloride	FILM;BUCCAL, SUBLINGUAL	215390-002	Apr 5, 2022		RX	Yes	No	⤷ Start Trial	⤷ Start Trial				ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER BY SUBLINGUAL OR BUCCAL ADMINISTRATION IN PATIENTS WITH SEVERE HEPATIC IMPAIRMENT	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Details for Patent: 11,806,334

Which drugs does patent 11,806,334 protect, and when does it expire?

Summary for Patent: 11,806,334